A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases

References

• Verstockt B, Van Assche G, Vermeire S, et al. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther. 2017 Jan;17(1):31–47.
   PubMed Web of Science ®Google Scholar
• Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis. 2006 Jun;19(3):245–252.
   PubMed Web of Science ®Google Scholar
• Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr. 2014 Oct;105(Suppl 1):34–40.
   PubMedGoogle Scholar
• Kisand K, Boe Wolff AS, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010 Feb 15;207(2):299–308.
   PubMed Web of Science ®Google Scholar
• Puel A, Doffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010 Feb 15;207(2):291–297.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May;66(5):742–751.
   PubMed Web of Science ®Google Scholar
• Khanna R, Preiss JC, MacDonald JK, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;5:CD007572.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008 Oct;135(4):1130–1141.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012 Oct;367(16):1519–1528.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016 Nov 17;375(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Rutgeers P, Gasink C, et al. Long term efficacy and safety of ustekinumab for Crohn’s disease: results from IM-UNITI long-term extension through 2 years. ECCO 2017. Barcelona; 2017.
   Google Scholar
• Loftus E, Augustin M, Bissoneete R, et al. Prevalence of inflammatory bowel disease amongst patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR registry. 11th Congress of ECCO (European Crohn’s and Colitis Organisation). Amsterdam; 2016.
   Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013 Apr;168(4):844–854.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Griffiths CE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012 May;66(5):731–741.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007 Feb 08;356(6):580–592.
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008 Sep;7(9):796–804.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014 Jun;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies. 11th Congress of ECCO. Amsterdam; 2016.
   Google Scholar
• Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011 Sep;63(3):154–163.
   PubMed Web of Science ®Google Scholar
• Loftus E, Sloan S, Ramachandran P, et al. Comparison of rates of active tuberculosis infection in the phase 2 and 3 clinical trial programs for anti-IL12/23 and anti-TNFS. DDW 2017. Chicago, USA; 2017.
   Google Scholar
• Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012 Nov;167(5):1145–1152.
   PubMed Web of Science ®Google Scholar
• Jones LL, Vignali DA. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res. 2011 Oct;51(1):5–14.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015 Jul;14(7):706–714.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. Jama. 2011 Aug;306(8):864–871.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013 May;27(5):622–627.
   PubMed Web of Science ®Google Scholar
• Rungapiromnan W, Yiu ZZ, Warren RB, et al. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomised controlled trials. Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011 Apr;164(4):862–872.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Trigoni A, et al. Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol. 2012 Jul 01;4(3):320–323.
   PubMedGoogle Scholar
• European Medicines Agency. Assessment report Stelara. [cited 2017 March 16]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000958/WC500163376.pdf
   Google Scholar
• Sandborn W, Feagan B, Gasink C, et al. A phase 3, randomized, multicenter, double-blind, placebo-controlled, study of ustekinumab maintenance therapy in moderate-severe Crohn’s disease patients: results from IM-UNITI. DDW 2016. San Diego; 2016.
   Google Scholar
• Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease. J Crohns Colitis. 2014 Sep;8(9):1138–1139.
   PubMed Web of Science ®Google Scholar
• Gratton D, Szapary P, Goyal K, et al. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol. 2011 Oct;147(10):1197–1202.
   PubMed Web of Science ®Google Scholar
• LiverTox. Clinical and Research Information on Drug-induced Liver Injury. [cited 2017 Mar 15]. Available from: https://livertox.nlm.nih.gov/
   Google Scholar
• Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011 Jul;29(7):615–624.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014 Nov;8(11):1516–1522.
   PubMed Web of Science ®Google Scholar
• Ginard D, Khorrami S, Marin I, et al. Effectiveness and safety of ustekinumab as rescue therapy in multi-drug resistant Crohn’s disease. 10th Congress of ECCO. Barcelona; 2015.
   Google Scholar
• Herrera C, Jimenez C, Casellas F, et al. Ustekinumab in super-refractory Crohn’s disease. 10th Congress of ECCO. Barcelona; 2015.
   Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016 Feb;14(2):242–50.e2.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Long-term efficacy and safety of ustekinumab in refractory Crohn’s disease patients: a multicenter retrospective experience. 12th Congress of ECCO (European Crohn’s and Colitis Organisation). Barcelona; 2017.
   Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017 May;45(9):1232-1243. doi: 10.1111/apt.14016. Epub 2017 Mar 2.
   Web of Science ®Google Scholar
• Janssen Biotech Inc. Stelara prescribing information. [cited 2017 Mar 16]. Available from: http://www.stelarahcp.com/pdf/PrescribingInformation.pdf
   Google Scholar
• Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010 Oct;89(5):351–363.
   PubMed Web of Science ®Google Scholar
• Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013 Aug;5(8):803–815.
   PubMed Web of Science ®Google Scholar
• Galli-Novak E, Mook SC, Büning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016 Dec;30(12):e191–e192.
   Web of Science ®Google Scholar
• Sheeran C, Nicolopoulos J. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol. 2014 Aug;55(3):235–236.
   PubMed Web of Science ®Google Scholar
• Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012 Oct;11(10):1240.
   PubMed Web of Science ®Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, et al. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012 Dec;6(4):105–107.
   PubMedGoogle Scholar
• Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016 Mar;30(3):488–490.
   PubMed Web of Science ®Google Scholar
• Rocha K, Piccinin MC, Kalache LF, et al. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology. 2015;231(2):103–104.
   PubMed Web of Science ®Google Scholar
• Cortes X, Borras-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017 Apr;42(2):234–236.
   PubMed Web of Science ®Google Scholar
• Clinical trials database. [cited 2017 Mar 16]. Available from: http://www.clinicaltrials.gov/
   Google Scholar
• Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014 Sep;171(3):485–491.
   PubMed Web of Science ®Google Scholar
• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 May;75(5):795–810.
   PubMed Web of Science ®Google Scholar
• USA Food and Drug Administration F. Stelara (ustekinumab) Prescribing information. [cited 2017 Mar 16]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125261s086lbl.pdf
   Google Scholar
• Janssen Biotech Inc. Stelara solution for injecting PRESCRIBING INFORMATION. [cited 2017 Mar 16]. Available from: http://www.janssen-pi.co.uk/stelara/
   Google Scholar
• Rinawi F, Rosenbach Y, Assa A, et al. Ustekinumab for resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):e34–e35.
   PubMed Web of Science ®Google Scholar
• Cameron FL, Garrick V, Russell RK. Ustekinumab in treatment of refractory paediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):e30.
   PubMed Web of Science ®Google Scholar
• Bishop C, Simon H, Suskind D, et al. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2016 Sep;63(3):348–351.
   PubMed Web of Science ®Google Scholar
• Olbjorn C, Rove JB, Jahnsen J Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab. European Crohn’s and Colitis Organisation 2017. Barcelona; 2017.
   Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015 Oct;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Koskinas J, Tampaki M, Doumba PP, et al. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol. 2013 Mar;168(3):679–680.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013 Dec;169(6):1295–1303.
   PubMed Web of Science ®Google Scholar
• Lightner A, Raffals L, Pemberton J, et al. P-143 does ustekinumab affect postoperative outcomes in patients undergoing abdominal operations for Crohn’s Disease? Inflamm Bowel Dis. 2017;23:S50.
   Web of Science ®Google Scholar
• Shim H, AlFarhan H, Aldarmaki A, et al. Preoperative ustekinumab treatment is not associated with increased postoperative complications in Crohn’s disease: a Canadian multicentre observational cohort study. Digestive Disease Week 2017. Chicago; 2017.
   Google Scholar
• Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017 Jan;26(1):28–35.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ustekinumab - Annex 1: SUMMARY OF PRODUCT CHARACTERISTICS. [cited 2017 Mar 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf
   Google Scholar
• Brodmerkel C, Wadman E, Langley RG, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013 Oct;12(10):1122–1129.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Jul;75(1):83–98e4.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Gomez-Garcia F, Epstein D, Isla-Tejera B, et al. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Br J Dermatol. 2017 Mar;176(3):594–603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13.
   PubMed Web of Science ®Google Scholar
• Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016 Oct;15(10):1413–1420.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010 Oct;2(52):52ra72.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sendid B, Jouault T, et al. Secukinumab failure in Crohn’s disease: the yeast connection? Gut. 2013 May;62(5):800–801.
   PubMed Web of Science ®Google Scholar
• Targan S, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s disease. Gastroenterology. 2012;143(3):e26.
   Google Scholar
• Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig. 2017 Feb 14;37:439–451.
   PubMed Web of Science ®Google Scholar
• Raine T, Kaser A. Seventeen in Crohn’s disease: less prime than we thought? Gut. 2012 Dec;61(12):1653–1654.
   PubMed Web of Science ®Google Scholar
• Kaser A. Not all monoclonals are created equal - lessons from failed drug trials in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2014 Jun;28(3):437–449.
   PubMed Web of Science ®Google Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013 Jan;133(1):17–26.
   PubMed Web of Science ®Google Scholar
• Baeten DL, Kuchroo VK. How Cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013 Jul;19(7):824–825.
   PubMed Web of Science ®Google Scholar
• Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006 May;116(5):1310–1316.
   PubMed Web of Science ®Google Scholar
• Sands B, Chen J, Penney J. A randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy. J Crohn’s Colitis. 2015;9(Suppl 1):S15–S16.
   Google Scholar
• Feagan B, Sandborn W, Panes J, et al. Efficacy and safety of induction therapy with the selective IL-23 inhibitor risankizumab (BI 655066) in patients with moderate-to-severe Crohn’s disease: results of a randomized, double-blind, placebo controlled Phase II study. DDW 2016. San Diego; 2016.
   Google Scholar
• Merck. [cited 2017 Mar 16]. Available from: http://www.merck.com/licensing/our-partnership/sunpharma_partnership.html
   Google Scholar
• Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930–939.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Calderon C, Marciniak SJ Jr., et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016 Nov;72(11):1303–1310.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Yzet C, Dupas JL, Fumery M. Ustekinumab and Anti-TNF combination therapy in patients with inflammatory bowel disease. Am J Gastroenterol. 2016 May;111(5):748–749.
   PubMed Web of Science ®Google Scholar
• Mocko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis. Pharmacol Rep. 2016 Dec;68(6):1237–1243.
   PubMed Web of Science ®Google Scholar
• Mansouri Y, Goldenberg G. Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Dermatol. 2015 Feb;8(2):30–42.
   PubMedGoogle Scholar